- Home
- USEG vs AXDX Comparison
USEG vs AXDX Comparison
Compare USEG & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEG
- AXDX
- Stock Information
- Founded
- USEG 1966
- AXDX 1982
- Country
- USEG United States
- AXDX United States
- Employees
- USEG N/A
- AXDX N/A
- Industry
- USEG Oil & Gas Production
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- USEG Energy
- AXDX Industrials
- Exchange
- USEG Nasdaq
- AXDX Nasdaq
- Market Cap
- USEG 39.8M
- AXDX 44.5M
- IPO Year
- USEG N/A
- AXDX 1996
- Fundamental
- Price
- USEG $1.67
- AXDX $1.85
- Analyst Decision
- USEG Strong Buy
- AXDX Hold
- Analyst Count
- USEG 2
- AXDX 1
- Target Price
- USEG $2.00
- AXDX $1.00
- AVG Volume (30 Days)
- USEG 100.1K
- AXDX 61.8K
- Earning Date
- USEG 11-12-2024
- AXDX 11-07-2024
- Dividend Yield
- USEG N/A
- AXDX N/A
- EPS Growth
- USEG N/A
- AXDX N/A
- EPS
- USEG N/A
- AXDX N/A
- Revenue
- USEG $21,611,000.00
- AXDX $11,909,000.00
- Revenue This Year
- USEG N/A
- AXDX $1.42
- Revenue Next Year
- USEG $8.50
- AXDX $4.09
- P/E Ratio
- USEG N/A
- AXDX N/A
- Revenue Growth
- USEG N/A
- AXDX N/A
- 52 Week Low
- USEG $0.81
- AXDX $0.73
- 52 Week High
- USEG $1.73
- AXDX $5.52
- Technical
- Relative Strength Index (RSI)
- USEG 66.68
- AXDX 48.99
- Support Level
- USEG $1.36
- AXDX $1.77
- Resistance Level
- USEG $1.45
- AXDX $2.04
- Average True Range (ATR)
- USEG 0.10
- AXDX 0.11
- MACD
- USEG 0.01
- AXDX -0.01
- Stochastic Oscillator
- USEG 85.71
- AXDX 29.63
About USEG U.S. Energy Corp. (DE)
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business activities in South Texas and the Williston Basin in North Dakota. The company generates revenue from its interest in the sales of oil and natural gas production.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.